These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 7831443)

  • 61. Can antipsychotic treatment contribute to drug addiction in schizophrenia?
    Samaha AN
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():9-16. PubMed ID: 23793001
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P; Waters N; Schmidt CJ; Carlsson A; Carlsson ML
    J Neural Transm (Vienna); 1998; 105(4-5):365-96. PubMed ID: 9720968
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characteristics of [14C]guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P.
    Emerit MB; Riad M; Fattaccini CM; Hamon M
    J Neurochem; 1993 Jun; 60(6):2059-67. PubMed ID: 7684066
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
    Millan MJ
    J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S; Stip E; Roy JY
    Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists.
    Tyers MB
    Therapie; 1991; 46(6):431-5. PubMed ID: 1840227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mediation of the antidepressant-like effect of 8-OH-DPAT in mice by postsynaptic 5-HT1A receptors.
    Luscombe GP; Martin KF; Hutchins LJ; Gosden J; Heal DJ
    Br J Pharmacol; 1993 Mar; 108(3):669-77. PubMed ID: 8467355
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons.
    Koulu M; Sjöholm B; Lappalainen J; Virtanen R
    Eur J Pharmacol; 1989 Oct; 169(2-3):321-4. PubMed ID: 2530097
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Role of 5-HT3 receptors in basal and K(+)-evoked dopamine release from rat olfactory tubercle and striatal slices.
    Zazpe A; Artaiz I; Del Río J
    Br J Pharmacol; 1994 Nov; 113(3):968-72. PubMed ID: 7858893
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 5-HT3 receptor over-expression decreases ethanol self administration in transgenic mice.
    Engel SR; Lyons CR; Allan AM
    Psychopharmacology (Berl); 1998 Nov; 140(2):243-8. PubMed ID: 9860116
    [TBL] [Abstract][Full Text] [Related]  

  • 75. There is more to dopamine than just pleasure. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'.
    Lingford-Hughes A
    Behav Pharmacol; 2002 Sep; 13(5-6):367-70. PubMed ID: 12394412
    [No Abstract]   [Full Text] [Related]  

  • 76. Hypothesis that mesolimbic dopamine (DA) plays a key role in mediating the reinforcing effects of drugs of abuse as well as the rewarding effects of ingestive behaviors.
    Rothman RB; Gendron T; Hitzig P
    J Subst Abuse Treat; 1994; 11(3):273-5. PubMed ID: 8072057
    [No Abstract]   [Full Text] [Related]  

  • 77. Dopamine: the rewarding years.
    Marsden CA
    Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S136-44. PubMed ID: 16402097
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Mechanisms and abuse liability of the anti-histamine dimenhydrinate.
    Halpert AG; Olmstead MC; Beninger RJ
    Neurosci Biobehav Rev; 2002 Jan; 26(1):61-7. PubMed ID: 11835984
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.
    Brisch R; Saniotis A; Wolf R; Bielau H; Bernstein HG; Steiner J; Bogerts B; Braun K; Jankowski Z; Kumaratilake J; Henneberg M; Gos T
    Front Psychiatry; 2014; 5():47. PubMed ID: 24904434
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dopamine and cognition.
    Robbins TW
    Curr Opin Neurol; 2003 Dec; 16 Suppl 2():S1-2. PubMed ID: 15129843
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.